Within the kidney, FXR activation downregulates lipogenic and fibrotic genes and reduces diabetes and obesity-related changes including glomerulosclerosis, tubulointerstitial fibrosis and proteinuria [21–26]. Here, NR1H4 is linked to obesity due to melanocortin 4 receptor deficiency.